NPI-0052

Published: Nov 4, 2009 11:33 am
Brand Name:
Generic Name:
Code Name: NPI-0052
Company: Nereus Pharmaceuticals
FDA Clinical Phase: 1

Description:
NPI-0052 is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. NPI-0052 may be used as an alternative treatment to Velcade (bortezomib), the first approved proteasome inhibitor, because it has shown significant activity against multiple myeloma that was previously resistant to Velcade. NPI-0052 is often administered orally or intravenously as either a single agent or in combination with other anti-cancer agents.

Clinical Trials:
Currently, there are currently several open clinical studies involving NPI-0052.

Official Web site for NPI-0052: http://www.nereuspharm.com/NPI-0052.shtml

Updated November 4, 2009

Related Articles:

Leave a comment

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.